

Medicines Patent Pool Governance Board Meeting #29

October 13, 2020
Hybrid meeting due to Covid-19

Attendees

Governance Board Members:

Dr Marie-Paule Kieny (Chair), Dr Manica Balasegaram, Mr Mohammed Barry, Dr Patrizia Carlevaro, Dr Claudia Chamas, Dr Jinliang Li, Dr Anban Pillay and Ms Jayashree Watal.

Non-voting members:

Mr Maximiliano Santa Cruz*, Dr Mariângela Batista Galvão Simão - WHO observer*, Mr Jan Akko Eleveld – Unitaïd Project Team, Mr Robert Matiru – Unitaïd Executive Team and Dr Luis Pizarro de Trenqualye – Unitaïd Executive Team.

Medicines Patent Pool Team:


Charles Gore – Executive Director, Karine Belondrade – Head of Strategy, Operations and Resource Mobilisation, Esteban Burrone – Head of Policy, Vincent Chauvin – CFO, Head of Human Resources, Gelise McCullough – Head of Communications, Sandra Nobre – Head of Business Development and Chan Park – General Counsel.

**These individuals attended part of the Board meeting only*

Summary of Decisions

The Governance Board of the Medicines Patent Pool Foundation:

1. Approves and adopts the minutes of Governance Board meeting #26 held on 27th April 2020, #27 held on 27th May 2020 and #28 held on 30th July 2020. The Board also approves the agenda of the Governance Board Meeting #29.
2. Agrees to continue the exploration of the biotherapeutics field. In particular the Board requests the Management to interview originators to assess their potential willingness to license and the extent of possible technology transfer, and to examine at least two specific case studies (one in HIV and one for an NCD) to assess in detail the potential for an MPP intervention. The Board requests an interim report in April 2021 on the discussions with originators and a final full report in October 2021 that will allow the Board to take a decision on MPP's role in biologics, if any.
3. Agrees to put on hold MPP's exploration of the vaccine field for the time being and concentrate on continuing its exploration in the area of biosimilars. Recognising that opportunities for intervention might arise in the future, the Board further agrees that



this decision does not apply to the COVID-19 field or if a specific request for support is made to MPP.

4. Agrees that MPP continues to look for, take advantage of, and secure funding for, opportunities for MPP's contribution to COVID-19. The Board further agrees to amend the March resolution as follows: "In response to the exceptional need for health technologies for the world to respond to Covid-19, the Board authorises the continuation of the temporary expansion of MPP's remit to include any health technologies where licensing could improve access for LMICs in coordination with the Access to COVID-19 Tools Accelerator partners. This Board resolution may be amended at any time but in any case will be reviewed at the April 2021 Board meeting."